Furthermore, we demonstrated in both BRAFV600E CRC cell line xenograft mouse models and PDXs that dual inhibition of SRC and BRAF synergistically reduced tumor growth compared with single-drug therapy. Here, BRAF is linked to colorectal carcinoma.